Mylan NV

Find more results for NYSE:MYL

Officers and directors

Robert J. Coury
Chairman of the Board
Rajiv Malik
President, Director
Heather M. Bresch
Chief Executive Officer, Director
Rodney L. Piatt CPA
Vice Chairman of the Board, Lead Independent Director
Kenneth Scott Parks
Chief Financial Officer
Rakesh Bamzai
President - India Commercial and Emerging Markets
Anthony Mauro
Chief Commercial Officer
Wendy Cameron
Independent Director
Robert J. Cindrich
Independent Director
Neil F. Dimick CPA
Independent Director


Unit 4, Trident Place, Mosquito Way
United Kingdom - Map
+44-1707-853000 (Phone)
+44-1707-643148 (Fax)

Website links

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Related companies

* Delayed by up to 20 minutes -  Disclaimer